ATE250138T1 - Angiogenese-inhibierende antikörper - Google Patents
Angiogenese-inhibierende antikörperInfo
- Publication number
- ATE250138T1 ATE250138T1 AT93923976T AT93923976T ATE250138T1 AT E250138 T1 ATE250138 T1 AT E250138T1 AT 93923976 T AT93923976 T AT 93923976T AT 93923976 T AT93923976 T AT 93923976T AT E250138 T1 ATE250138 T1 AT E250138T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- angiogenesis
- endothelial cells
- sec
- date
- Prior art date
Links
- 210000002889 endothelial cell Anatomy 0.000 abstract 3
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 210000001644 umbilical artery Anatomy 0.000 abstract 1
- 210000003606 umbilical vein Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL557392 | 1992-10-29 | ||
PCT/AU1993/000558 WO1994010331A1 (en) | 1992-10-29 | 1993-10-29 | Angiogenesis inhibitory antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE250138T1 true ATE250138T1 (de) | 2003-10-15 |
Family
ID=3776506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93923976T ATE250138T1 (de) | 1992-10-29 | 1993-10-29 | Angiogenese-inhibierende antikörper |
Country Status (9)
Country | Link |
---|---|
US (2) | US5677181A (de) |
EP (1) | EP0669988B2 (de) |
JP (1) | JP3490443B2 (de) |
AT (1) | ATE250138T1 (de) |
AU (1) | AU673865B2 (de) |
CA (1) | CA2148244A1 (de) |
DE (1) | DE69333209T2 (de) |
SG (1) | SG78239A1 (de) |
WO (1) | WO1994010331A1 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
SG78239A1 (en) * | 1992-10-29 | 2001-02-20 | Univ Australian | Angiogenesis inhibitory antibodies |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
ES2188202T3 (es) | 1998-07-13 | 2003-06-16 | Univ Texas | Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos. |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
WO2000002584A2 (en) | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
EP2298334A3 (de) * | 1999-12-20 | 2012-04-04 | Immunex Corporation | Tweak Rezeptor |
US6727192B2 (en) * | 2001-03-01 | 2004-04-27 | Micron Technology, Inc. | Methods of metal doping a chalcogenide material |
US20030139374A1 (en) * | 2001-09-27 | 2003-07-24 | Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. | Combined methods for tumor vasculature coagulation and treatment |
CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
EP1487492A4 (de) * | 2002-03-04 | 2008-10-01 | Medimmune Inc | Prävention oder behandlung von krebs mit integrin alphavbeta3 antagonisten in kombination mit anderen mitteln |
AU2003272449A1 (en) * | 2002-09-16 | 2004-04-30 | Exelixis, Inc. | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US7285268B2 (en) | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
AU2004207002A1 (en) * | 2003-01-30 | 2004-08-12 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
EP1625165A2 (de) * | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Integrin alpha5beta1 inhibitoren und deren verwendung zur kontrolle der gewebe-granulation |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
CA2530533C (en) | 2003-06-27 | 2015-02-10 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
AU2005322060B2 (en) | 2003-06-27 | 2011-11-17 | Ethicon Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US7662384B2 (en) * | 2004-03-24 | 2010-02-16 | Facet Biotech Corporation | Use of anti-α5β1 antibodies to inhibit cancer cell proliferation |
PL1819358T3 (pl) | 2004-11-18 | 2015-02-27 | Imclone Llc | Przeciwciała przeciwko czynnikowi wzrostu śródbłonka naczyniowego |
IL165365A0 (en) | 2004-11-24 | 2006-01-15 | Q Core Ltd | Finger-type peristaltic pump |
PL1835924T3 (pl) | 2004-12-23 | 2014-01-31 | Ethicon Incorporated | Leczenie choroby Parkinsona i zaburzeń związanych z tą chorobą z użyciem komórek uzyskiwanych po porodzie |
US9175261B2 (en) | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
JP5179376B2 (ja) | 2005-12-19 | 2013-04-10 | エシコン・インコーポレイテッド | ローラーボトルでの分娩後取り出し細胞の体外増殖 |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
WO2009018226A2 (en) * | 2007-07-27 | 2009-02-05 | Facet Biotech Corporation | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e) |
US8034329B2 (en) | 2007-10-05 | 2011-10-11 | Advanced Technologies And Regenerative Medicine, Llc | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
SG174551A1 (en) | 2009-03-26 | 2011-10-28 | Ethicon Inc | Human umbilical cord tissue cells as therapy for alzheimer' s disease |
BR112014015424A2 (pt) | 2011-12-23 | 2018-05-22 | Depuy Synthes Products Llc | detecção de células derivadas de tecido do cordão umbilical humano |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4721672A (en) * | 1985-08-28 | 1988-01-26 | President And Fellows Of Harvard College | CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression |
US5512660A (en) * | 1987-05-04 | 1996-04-30 | Dana Farber Cancer Institute, Inc. | Purified ICAM-2 and fragment thereof |
AU2807189A (en) † | 1987-11-19 | 1989-07-05 | Scripps Clinic And Research Foundation | Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells |
ATE174223T1 (de) * | 1989-04-10 | 1998-12-15 | Oncogen | Verwendung von oncostatin m zur suppression von mhc antigenen |
US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
IT1239065B (it) * | 1990-05-14 | 1993-09-20 | Fidia Spa | Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4 |
EP0505749A3 (en) * | 1991-02-26 | 1993-06-23 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use |
SG78239A1 (en) * | 1992-10-29 | 2001-02-20 | Univ Australian | Angiogenesis inhibitory antibodies |
-
1993
- 1993-10-29 SG SG1996000859A patent/SG78239A1/en unknown
- 1993-10-29 CA CA002148244A patent/CA2148244A1/en not_active Withdrawn
- 1993-10-29 WO PCT/AU1993/000558 patent/WO1994010331A1/en active IP Right Grant
- 1993-10-29 US US08/433,423 patent/US5677181A/en not_active Expired - Lifetime
- 1993-10-29 AT AT93923976T patent/ATE250138T1/de not_active IP Right Cessation
- 1993-10-29 EP EP93923976A patent/EP0669988B2/de not_active Expired - Lifetime
- 1993-10-29 JP JP51046794A patent/JP3490443B2/ja not_active Expired - Fee Related
- 1993-10-29 DE DE69333209T patent/DE69333209T2/de not_active Expired - Lifetime
- 1993-10-29 AU AU53661/94A patent/AU673865B2/en not_active Ceased
-
1997
- 1997-03-13 US US08/815,933 patent/US5874081A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5677181A (en) | 1997-10-14 |
EP0669988B1 (de) | 2003-09-17 |
AU5366194A (en) | 1994-05-24 |
US5874081A (en) | 1999-02-23 |
JP3490443B2 (ja) | 2004-01-26 |
JPH08502409A (ja) | 1996-03-19 |
EP0669988B2 (de) | 2009-07-08 |
EP0669988A4 (de) | 1996-07-31 |
AU673865B2 (en) | 1996-11-28 |
DE69333209T2 (de) | 2004-07-01 |
EP0669988A1 (de) | 1995-09-06 |
SG78239A1 (en) | 2001-02-20 |
DE69333209D1 (de) | 2003-10-23 |
WO1994010331A1 (en) | 1994-05-11 |
CA2148244A1 (en) | 1994-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE250138T1 (de) | Angiogenese-inhibierende antikörper | |
Jiang et al. | Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. | |
Johansson et al. | Comparison of fibronectin receptors from rat hepatocytes and fibroblasts. | |
ATE163533T1 (de) | Schwungphasensteuervorrichtung | |
ATE178907T1 (de) | Rezeptorbindende region des diphtherietoxius | |
DE69838454D1 (de) | Natürlicher menschlicher antikörper | |
ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
RS51273B (sr) | Konjugati nosač-hapten za tretman i prevenciju zavisnosti od nikotina | |
RU94045908A (ru) | Композиция, способ обработки неопластической клетки, способ уничтожения неопластической клетки | |
ATE314475T1 (de) | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität | |
DK0703802T3 (da) | Intravaginalt system til afgivelse af aktivt stof | |
PT861892E (pt) | Epitopos das proteinas do stress | |
SE9500385L (sv) | Absorberande byxprodukt | |
DK151687A (da) | Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf | |
ATE210127T1 (de) | 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung | |
DE69328550T2 (de) | Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln | |
ATE204480T1 (de) | Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon | |
DK0807125T3 (da) | Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis | |
ES2058599T3 (es) | Procedimiento para mejorar la eficacia de las toxinas de insectos. | |
DE68918944T2 (de) | Künstliche rezeptor-analoge. | |
DE69330352T2 (de) | Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut | |
DK0478631T3 (da) | Målsøgende midler | |
DK0821593T3 (da) | Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein | |
DE69434087D1 (de) | ENTEROTOXINE VON SHIGELLA FLEXNERI 2a | |
FI974018A (fi) | Ihmisen 2 integriini -alayksikkö |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |